Core Insights - Zelluna has promoted Emilie Gauthy to Chief Technology Officer (CTO), effective immediately, recognizing her contributions to the company's manufacturing and CMC capabilities since joining in 2022 [1][4] Company Developments - As CTO, Gauthy will lead Zelluna's manufacturing and CMC strategy, focusing on advancing the clinical development program, scaling up manufacturing capacity, and expanding the TCR-NK pipeline [2] - Under Gauthy's leadership, Zelluna has established a scalable manufacturing process and analytical capabilities, which facilitated the submission of its Clinical Trial Application (CTA) for ZI-MA4-1 to the UK MHRA in December 2025 [3] - Key achievements include locking the manufacturing process, producing and quality-testing a GMP clinical batch, and establishing the CMC foundation for the first-in-human clinical trial, with initial data expected from mid-2026 [3] Leadership Statements - CEO Namir Hassan highlighted Gauthy's central role in building the manufacturing and CMC capabilities that enabled the submission of the first CTA, emphasizing her leadership in establishing the foundation for clinical development [4] - Emilie Gauthy expressed pride in the team's achievements since 2022, noting the submission of the first CTA as a major milestone and the strong manufacturing foundations built for the scalable TCR-NK platform [4] Company Overview - Zelluna ASA is pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for solid cancers, with its lead candidate ZI-MA4-1 being the world's first MAGE-A4 targeting TCR-NK therapy [5] - The company submitted its Clinical Trial Application to the UK MHRA in December 2025, with initial clinical data expected to emerge from mid-2026 [5]